

JUL 23 2004

510(k) Summary of Safety and Effectiveness

Date: June 10, 2004

Submitter: Patient Monitoring Division
Datascope Corp.

Contact Person: Susan E. Mandy
Director, Clinical & Regulatory Affairs
Patient Monitoring Division
Datascope Corp.
Telephone: (201) 995-8025
Fax: (201) 995-8605

Device trade name: Trio Monitor

Common/usual name: Physiological Patient Monitor

Classification name:

21 CFR 870.1100 Blood pressure alarm
21 CFR 870.1130 Noninvasive blood pressure measurement systems
21 CFR 870.1110 Blood pressure computer
21 CFR 870.2300 Cardiac monitor (including cardiometer and rate alarm)
21 CFR 870.2340 Electrocardiograph
21 CFR 870.2700 Oximeter
21 CFR 880.2910 Clinical electronic thermometers

Predicate Device: Datascope Trio Monitor, 510(k) K032338 (FDA determination of substantial equivalence, February 11, 2004)
Datascope Passport 2, 510(k) K993531 (FDA determination of substantial equivalence, January 13, 2000)

Device Description: Mindray Bio-Medical Co. Ltd., previously known as Caymans Mindray Medical Electronic Company of Shenzhen, China, manufactures the Trio monitor for Datascope Corp.

Background:

The FDA cleared the Trio monitor to market under 510(k) K032338 on February 11, 2004. Datascope Corp. has modified the Trio monitor to include Heart Rate derived from Non-Invasive Blood Pressure. Datascope has also made some minor modifications to the Trio monitor as a result of feedback received from both domestic and international customers, and from an October 2002 focus group, referenced on page 228 of K032338, submitted to the FDA on July 28, 2003. These modifications include the replacement of the "Freeze" key with a "Normal Screen" key, minor user interface display formatting modifications, e.g., changes to fonts, colors, screen layout, as well as user preferred default selections.

Purpose:

The ability to derive Heart Rate from the Non-Invasive Blood Pressure parameter is the subject of this 510(k) submission. In the previous Trio submission, Heart Rate was derived from ECG and SpO₂. The description of the Trio monitor remains the same as in the original 510(k) K032338, submitted to the FDA, July 28, 2003 and is provided below. Datascope Corp. incorporates by reference Trio monitor 510(k) submission K0323338.

The Trio monitor is a three or four trace patient monitor that can be mounted on a rolling stand, wall mount bracket, bed rail, or operated as a tabletop device. The patient parameters that can be monitored on the Trio are: ECG (3-lead or 5-lead selectable), Temperature, SpO₂, Invasive Blood Pressure, Respiration and Non-Invasive Blood Pressure. Digital displays are provided for Heart Rate, Pulse Rate, Pulse Oximetry, Non-Invasive Blood Pressure, Respiration Rate, Invasive Blood Pressure (optional) and Temperature. Waveform displays are provided for ECG, Pleth, Invasive Blood Pressure (optional) and Respiration. The optional built-in thermal recorder provides hard copies of all digital data and waveforms, as well as Tabular and Graphic Trend information.

Intended Use:

The Trio monitor is intended for use in healthcare settings under the direct supervision of a licensed healthcare practitioner. The intended use of the monitor is to monitor physiologic parameter data on adult and pediatric patients. Physiologic data includes: electrocardiogram, invasive blood pressure, non-invasive blood pressure (NIBP), pulse oximetry, heart rate (derived from ECG, SpO₂ or NIBP), respiration, and temperature as summarized in the operating instructions manual. The information can be displayed, stored, trended and printed.

Technology: The Trio monitor employs the same functional technology as the predicate devices.

Test Summary: The Trio monitor complies with the voluntary standards identified in section six of this submission. During the development process of the Trio monitor described in K032338, the following activities were completed:

- Requirements specification review
- Hardware and software testing
- Code design and code reviews
- Environmental testing
- Safety testing
- Performance testing
- Risk Analysis
- Hardware and Software validation

Testing and documentation, related to the ability of the Trio monitor to derive Heart Rate from Non-Invasive Blood Pressure, is included in this 510(k) submission, sections five, seven, and eight.

Conclusion: The results of these measurements demonstrated that the Trio monitor is as safe, as effective and performs as well, as the predicate devices.



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

JUL 23 2004

Datascope Corp.
c/o Mr. Bahram Barzideh
Underwriters Laboratories, Inc.
1285 Walt Whitman Rd.
Melville, NY 11747

Re: K041907

Trade Name: Trio Monitor
Regulation Number: 21 CFR 870.2300
Regulation Name: Cardiac Monitor (including cardiometer and rate alarm)
Regulatory Class: II (two)
Product Code: MWI
Dated: July 13, 2004
Received: July 15, 2004

Dear Mr. Barzideh:


We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (301) 594-4648. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/dsma/dsmamain.html>

Sincerely yours,

A handwritten signature in black ink, appearing to read "Bram D. Zuckerman", followed by a small flourish.

Bram D. Zuckerman, M.D.

Director

Division of Cardiovascular Devices

Office of Device Evaluation

Center for Devices and

Radiological Health

Enclosure

Indication for Use510(k) Number (if known): K041907Device Name: Trio Monitor

Indications for Use:

INDICATION FOR USE STATEMENT

The Trio™ monitor is intended for use in healthcare settings under the direct supervision of a licensed healthcare practitioner. The intended use of the monitor is to monitor physiologic parameter data on adult and pediatric patients. Physiologic data includes: electrocardiogram, invasive blood pressure, non-invasive blood pressure (NIBP), pulse oximetry, heart rate (derived from ECG, SpO₂ or NIBP), respiration and temperature as summarized in the operating instructions manual. The information can be displayed, stored, trended and printed.

The monitor is not intended for home use. The monitor is not intended to be an apnea monitor. It was not designed or validated for use as an apnea monitor

Prescription Use X AND/OR Over-The-Counter Use
(Part 21 CFR 801 Subpart D) (21 CFR 807 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Neil R. Soder Sr. 902
(Division Sign-Off)
Division of Cardiovascular Devices

510(k) Number K041907